Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people

Imagem de Miniatura
Arquivos
art_OLIVEIRA_Weight_loss_and_improved_mood_after_aerobic_exercise_2019.PDF (2.06 MB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
OLIVEIRA, Ardo Belitardo de
MELLO, Marco Tulio de
TUFIK, Serio
Citação
PHYSIOLOGY & BEHAVIOR, v.201, p.191-197, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Anandamide, a major endocannabinoid, participates in energy metabolism homeostasis and neurobehavioral processes. In a secondary analysis of an open-label, randomized controlled trial, we investigated the long-term effect of aerobic exercise on resting plasma anandamide, and explored its relationship with changes in body weight, cardiorespiratory fitness, and mood status in healthy, physically inactive individuals. Participants recruited between March 2013 to August 2015 at the UNIFESP's Neurology/Psychobiology Department were randomly allocated into a 12-weeks supervised moderate exercise program, or into waitlist, control condition. Thirty-four participants (age = 38 +/- 11.5, BMI = 26.6 +/- 3.6) were intention to treat-analysed (Exercise: n = 17; Control: n = 17). After intervention, there were significant decreases in plasma anandamide (p < .01), anger, anxiety, and body weight (all p < .05), whereas cardiorespiratory fitness increased (p < .05) in the exercise group. There were no significant changes in any variable for the control group. In the whole cohort, adjusted R-2 of multiple linear regressions showed that 12.2% of change body weight was explained by changes in anandamide (beta = 0.391, p = .033), while 27% of change in mood disturbance (beta= 0. 546, p = .003), and 13.1% of change in anger (beta = 0.404, p = .03) was explained by changes in anandamide. Our data suggest that the weight loss and mood improvement through regular moderate exercise may involve changes in anandamide metabolism/signaling.
Palavras-chave
Endocannabinoids, Weight loss, Physical activity, Exercise, Mental Health, Peak Oxygen Uptake
URI
https://observatorio.fm.usp.br/handle/OPI/31836
Referências
  1. Addy C, 2008, CELL METAB, V7, P68, DOI 10.1016/j.cmet.2007.11.012
  2. Aguiar DC, 2014, NEUROSCI BIOBEHAV R, V46, P418, DOI 10.1016/j.neubiorev.2014.03.026
  3. Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69
  4. Bouaboula M, 2005, EUR J PHARMACOL, V517, P174, DOI 10.1016/j.ejphar.2005.05.032
  5. Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
  6. Brellenthin AG, 2017, MED SCI SPORT EXER, V49, P1688, DOI 10.1249/MSS.0000000000001276
  7. Cavuoto P, 2007, MOL CELL ENDOCRINOL, V267, P63, DOI 10.1016/j.mce.2006.12.038
  8. Crombie KM, 2018, J TRAUMA STRESS, V31, P134, DOI 10.1002/jts.22253
  9. Crosby KM, 2012, NEUROSCIENCE, V204, P31, DOI 10.1016/j.neuroscience.2011.11.049
  10. Di Marzo V, 2009, DIABETOLOGIA, V52, P213, DOI 10.1007/s00125-008-1178-6
  11. Dietrich A, 2004, BRIT J SPORT MED, V38, P536, DOI 10.1136/bjsm.2004.011718
  12. diTomaso E, 1996, NATURE, V382, P677, DOI 10.1038/382677a0
  13. Dlugos A, 2012, NEUROPSYCHOPHARMACOL, V37, P2416, DOI 10.1038/npp.2012.100
  14. Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838
  15. Evans S, 2007, PLOS CLIN TRIALS, V2, P1, DOI 10.1371/journal.pctr.0020018
  16. Gamelin FX, 2016, J PHYSIOL BIOCHEM, V72, P183, DOI 10.1007/s13105-016-0469-5
  17. Gasperi V, 2014, MED SCI SPORT EXER, V46, P24, DOI 10.1249/MSS.0b013e3182a10ce6
  18. Haring M, 2012, NEUROSCIENCE, V204, P145, DOI 10.1016/j.neuroscience.2011.12.035
  19. Heyman E, 2012, OBES REV, V13, P1110, DOI 10.1111/j.1467-789X.2012.01026.x
  20. Heyman E, 2012, PSYCHONEUROENDOCRINO, V37, P844, DOI 10.1016/j.psyneuen.2011.09.017
  21. Hill MN, 2012, NEUROSCIENCE, V204, P5, DOI 10.1016/j.neuroscience.2011.12.030
  22. Hutchins-Wiese HL, 2012, J NUTR BIOCHEM, V23, P986, DOI 10.1016/j.jnutbio.2011.05.005
  23. Kim J, 2011, NUTRITION, V27, P624, DOI 10.1016/j.nut.2010.11.003
  24. Lear SA, 2017, LANCET, V390, P2643, DOI 10.1016/S0140-6736(17)31634-3
  25. Lipina C, 2014, AM J PHYSIOL-ENDOC M, V307, pE1, DOI 10.1152/ajpendo.00100.2014
  26. Liu YL, 2005, INT J OBESITY, V29, P183, DOI 10.1038/sj.ijo.0802847
  27. Matias I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042399
  28. McNair D., 1971, PROFILE MOOD STATES, P1
  29. Methoulam R., 2002, PROSTAGLANDINS LEUKO, V66, P93
  30. Micale V, 2013, PHARMACOL THERAPEUT, V138, P18, DOI 10.1016/j.pharmthera.2012.12.002
  31. Antunes HKM, 2016, PHYSIOL BEHAV, V156, P182, DOI 10.1016/j.physbeh.2016.01.028
  32. Moreira FA, 2012, NEUROSCIENCE, V204, P186, DOI 10.1016/j.neuroscience.2011.08.046
  33. Oliveira AB, 2017, J NEUROIMMUNOL, V313, P138, DOI 10.1016/j.jneuroim.2017.09.008
  34. Raichlen DA, 2013, EUR J APPL PHYSIOL, V113, P869, DOI 10.1007/s00421-012-2495-5
  35. Raichlen DA, 2012, J EXP BIOL, V215, P1331, DOI 10.1242/jeb.063677
  36. Silvestri C, 2013, CELL METAB, V17, P475, DOI 10.1016/j.cmet.2013.03.001
  37. Sparling PB, 2003, NEUROREPORT, V14, P2209, DOI 10.1097/01.wnr.0000097048.56589.47
  38. Tantimonaco M, 2014, CELL MOL LIFE SCI, V71, P2681, DOI 10.1007/s00018-014-1575-6
  39. Taube A, 2009, AM J PHYSIOL-ENDOC M, V297, pE1004, DOI 10.1152/ajpendo.00241.2009
  40. Wahid A, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002495
  41. Zschucke Elisabeth, 2013, J Prev Med Public Health, V46 Suppl 1, pS12, DOI 10.3961/jpmph.2013.46.S.S12

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/21